Axl inhibitor therapeutic agent for solid cancers
Summary
The European Patent Office has granted Patent EP3695839A1 to ONO Pharmaceutical Co., Ltd. and Kyoto Prefectural Public University Corporation, covering an Axl inhibitor therapeutic agent for treating solid cancers. The patent protects novel compound compositions and their pharmaceutical applications. Designated states include all EU member states plus Switzerland, Norway, and other EPC contracting states.
What changed
The European Patent Office has published Patent EP3695839A1, granting exclusivity to ONO Pharmaceutical Co., Ltd. and Kyoto Prefectural Public University Corporation for Axl inhibitor compositions useful in treating solid cancers. The patent covers compounds classified under A61K 31/4709 and A61K 31/506 with claims to pharmaceutical compositions comprising C07D 401/14 derivatives.
Pharmaceutical companies developing Axl-targeted oncology therapeutics should assess freedom-to-operate and consider potential licensing negotiations with ONO Pharmaceutical. Competitors in the solid tumor treatment space may need to design around the granted claims or challenge the patent validity. Academic researchers and biotech firms working on receptor tyrosine kinase inhibitors should conduct thorough prior art searches to avoid infringement.
What to do next
- Monitor freedom-to-operate for Axl inhibitor development programs
- Review patent claims for competitive landscape analysis
- Evaluate licensing opportunities for therapeutic development
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
THERAPEUTIC AGENT FOR SOLID CANCERS WHICH COMPRISES AXL INHIBITOR AS ACTIVE
Publication EP3695839A1 Kind: A1 Apr 01, 2026
Applicants
ONO Pharmaceutical Co., Ltd., Kyoto Prefectural Public University Corporation
Inventors
TAKAYAMA, Koichi, YAMADA, Tadaaki, YASUHIRO, Tomoko, TANAKA, Kohei
IPC Classifications
A61K 31/4709 20060101AFI20210609BHEP A61K 31/506 20060101ALI20210609BHEP A61P 35/00 20060101ALI20210609BHEP A61P 43/00 20060101ALI20210609BHEP C07D 401/14 20060101ALI20210609BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.